Center for Esophageal Diseases and Swallowing and Center for Gastrointestinal Biology and Disease, Division of Gastroenterology and Hepatology, Department of Medicine, University of North Carolina School of Medicine, Chapel Hill, North Carolina.
Division of Gastroenterology and Hepatology, Northwestern University Feinberg School of Medicine, Chicago, Illinois.
Clin Gastroenterol Hepatol. 2022 Nov;20(11):2474-2484.e3. doi: 10.1016/j.cgh.2022.02.017. Epub 2022 Feb 16.
BACKGROUND & AIMS: Substantial heterogeneity in terminology used for eosinophilic gastrointestinal diseases (EGIDs), particularly the catchall term "eosinophilic gastroenteritis," limits clinical and research advances. We aimed to achieve an international consensus for standardized EGID nomenclature. METHODS: This consensus process utilized Delphi methodology. An initial naming framework was proposed and refined in iterative fashion, then assessed in a first round of Delphi voting. Results were discussed in 2 consensus meetings, and the framework was updated and reassessed in a second Delphi vote, with a 70% threshold set for agreement. RESULTS: Of 91 experts participating, 85 (93%) completed the first and 82 (90%) completed the second Delphi surveys. Consensus was reached on all but 2 statements. "EGID" was the preferred umbrella term for disorders of gastrointestinal (GI) tract eosinophilic inflammation in the absence of secondary causes (100% agreement). Involved GI tract segments will be named specifically and use an "Eo" abbreviation convention: eosinophilic gastritis (now abbreviated EoG), eosinophilic enteritis (EoN), and eosinophilic colitis (EoC). The term "eosinophilic gastroenteritis" is no longer preferred as the overall name (96% agreement). When >2 GI tract areas are involved, the name should reflect all of the involved areas. CONCLUSIONS: This international process resulted in consensus for updated EGID nomenclature for both clinical and research use. EGID will be the umbrella term, rather than "eosinophilic gastroenteritis," and specific naming conventions by location of GI tract involvement are recommended. As more data are developed, this framework can be updated to reflect best practices and the underlying science.
背景与目的:用于嗜酸性胃肠道疾病(EGIDs)的术语存在很大的异质性,尤其是“嗜酸性胃肠炎”这一统称,这限制了临床和研究进展。我们旨在为标准化 EGID 命名达成国际共识。
方法:本共识过程采用德尔菲法。最初提出了一个命名框架,并以迭代方式进行了改进,然后在第一轮德尔菲投票中进行了评估。结果在 2 次共识会议上进行了讨论,并在第二轮德尔菲投票中更新和重新评估了框架,设定了 70%的同意阈值。
结果:在参与的 91 名专家中,有 85 名(93%)完成了第一轮投票,82 名(90%)完成了第二轮投票。除了 2 条声明外,其他所有声明都达成了共识。“EGID”是胃肠道(GI)嗜酸性炎症无继发原因的疾病的首选总称(100%的同意率)。受累的 GI 节段将被具体命名,并使用“Eo”缩写约定:嗜酸性胃炎(缩写为 EoG)、嗜酸性肠炎(EoN)和嗜酸性结肠炎(EoC)。“嗜酸性胃肠炎”不再作为首选的总体名称(96%的同意率)。当涉及 2 个以上的 GI 区域时,名称应反映所有涉及的区域。
结论:这个国际过程达成了用于临床和研究用途的更新的 EGID 命名共识。EGID 将是总称,而不是“嗜酸性胃肠炎”,建议根据 GI 受累部位的位置采用特定的命名约定。随着更多数据的发展,该框架可以更新以反映最佳实践和基础科学。
Clin Gastroenterol Hepatol. 2022-11
Immunol Allergy Clin North Am. 2024-5
Ann Nutr Metab. 2019-2-19
Gastroenterol Hepatol (N Y). 2022-9
Singapore Med J. 2011-10
Gastroenterol Clin North Am. 2014-6
Joint Bone Spine. 2016-10
Immunol Allergy Clin North Am. 2024-5
J Allergy Clin Immunol. 2022-8
Curr Pediatr Rev. 2020
Gastroenterol Hepatol (N Y). 2025-8
Infect Drug Resist. 2025-8-13
Dis Esophagus. 2025-7-3
Medicine (Baltimore). 2025-7-18
J Gen Fam Med. 2025-2-14
Zhongguo Dang Dai Er Ke Za Zhi. 2025-4-15
J Allergy Clin Immunol Pract. 2021-9
Clin Gastroenterol Hepatol. 2022-3
J Allergy Clin Immunol Pract. 2021-5
N Engl J Med. 2020-10-22
Clin Gastroenterol Hepatol. 2021-10
J Pediatr Gastroenterol Nutr. 2020-10
J Allergy Clin Immunol Pract. 2020-6